Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05072444 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
A Phase 1 study, sponsored by Qpex Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05072444 is a Phase 1 study that has completed, run by Qpex Biopharma. The registered enrollment target is 12 participants.
The verdict
NCT05072444, a Phase 1 study, has completed, sponsored by Qpex Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum betalactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in Enterobacteriaceae and Pseudomonas aeruginosa (P. aeruginosa). QPX7728 is also a potent inhibitor of carbapenemases from all molecular classes, such as class A Klebsiella pheumoniae carbapenemase (KPC), class B New-Dehli Metalo-beta-lactamase (NDM) and Verona integron-encoded metallo-betalactamase (VIM), and class D OXA-48 that are found in carbapenem resistant Enterobacteriaceae, and also class D carbapenemases such as OXA-23 that are found in carbapenem resistant Acinetobacter baumannii.
Interventions
- DRUG QPX7728
- DRUG QPX2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05072444
The ClinicalTrials.gov registry entry for NCT05072444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qpex Biopharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QPX7728 is the first listed.
NCT05072444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05072444 about?
NCT05072444 is a clinical study titled "Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects". QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum betalactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in ...
What is the current status of trial NCT05072444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-11-15. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT05072444?
The interventions under investigation include: QPX7728 (DRUG), QPX2014 (DRUG).
Who is sponsoring clinical trial NCT05072444?
This trial is sponsored by Qpex Biopharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.